CN Patent

CN113209033A — Rucaparib的高剂量强度片剂

Assigned to Swiss Pharmaceutical Co ltd · Expires 2021-08-06 · 5y expired

What this patent protects

本发明涉及Rucaparib的高强度片剂，所述片剂包含45‑90％w/w的活性药物成分化合物8‑氟‑2‑{4‑[(甲基氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂并[5,4,3‑cd]吲哚‑6‑酮樟樟脑磺酸盐。

USPTO Abstract

本发明涉及Rucaparib的高强度片剂，所述片剂包含45‑90％w/w的活性药物成分化合物8‑氟‑2‑{4‑[(甲基氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂并[5,4,3‑cd]吲哚‑6‑酮樟樟脑磺酸盐。

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: CN113209033A
Jurisdiction: CN
Classification: —
Expires: 2021-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Swiss Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.